ADC Therapeutics SA 8-K

What Happened

• ADC Therapeutics SA (NASDAQ: ADCT) filed a Form 8-K on March 10, 2026 announcing the company's financial results for the fourth quarter and full year ended December 31, 2025. The company issued a press release on the same date; that release is attached to the filing as Exhibit 99.1. The report was signed by Chief Financial Officer Jose Carmona.

Key Details

• Filing date: March 10, 2026 (Form 8-K, Item 2.02 disclosure of results of operations and financial condition).
• Period covered: Fourth quarter and year ended December 31, 2025.
• Press release: Attached as Exhibit 99.1 to the 8-K.
• Signature: Filed and signed by Jose Carmona, Chief Financial Officer of ADC Therapeutics SA.

Why It Matters

• This 8-K notifies investors that ADC has publicly reported its latest quarterly and full-year financial results; the attached press release will contain the specific figures (revenue, earnings or losses, cash position, and any commentary on trends). Timely disclosure of these results can affect the stock price and gives investors up-to-date information to evaluate company performance and near-term outlook.